Table 1.

Summary of studies evaluating IFN-alpha treatment of chronic hepatitis D.

Treatment	Treatment modalities	Number of patients	Sustained suppression of HDV RNA at 24-weeks of follow-up	References
IFN-alpha: 3–18 Mio units 3x/week	3–12 months	201	17%	[129]
Pegylated IFN-alpha 2b: 1.5 µg/kg qw	18 months	16	25%	[137]
	18 months + Ribavirin (1–1.2 g qd for 12 months)	22	18%	[137]
	12 months	14	43%	[123]
	12 months	12	17%	[138]
	12 months	48	25%	[139]
Pegylated IFN-alpha 2a: 180 µg/kg qw	12 months	29	26%	[133]
	12 months + adefovir (10 mg qd for 12 months)	31	31%	[133]
Pegylated IFN-alpha 2b: 1.5 µg/kg qw or Pegylated IFN-alpha 2a: 180 µg/kg qw	12 months	104	23%	[140]

Abbreviations: qw, weekly; qd, daily.